A first-in-human clinical trial of iPS cell-derived invariant natural killer T cells in patients with recurrent head and neck cancer demonstrated safety and early signs of efficacy, showing tumor growth suppression and activation of immune pathways.
- Tomohisa Iinuma
- Tomoya Kurokawa
- Shinichiro Motohashi
